Article in CAP Today about liquid biopsy and the opportunity that tests like Biodesix's Genestrat offer to lung cancer treatment
Dr. Paul Walker describes how liquid biopsy testing helps battling lung cancer in the tobacco belt. The advantages of liquid biopsy for lung cancer.
Availability of biomarker data early in the treatment process enables tumor boards to review cases more efficiently and to better understand treatment options.
'Liquid biopsy really opens the possibility of a kind of real-time molecular analysis of the tumor to help inform treatment choices,' Dr. Burstein concluded.
ROS1 and RET mutations are now available in Biodesix's liquid biopsy test, GeneStrat
CGTV (China Television) story on Biodesix's agreement with Bioyong, and why lung cancer tests are needed in China
“VeriStrat appears to be a robust assay and should be used for EGFR wild-type patients with squamous cell lung cancer,” says study author Glenwood D. Goss, MD, professor of medicine and an oncologist
Biodesix wins IQ Award for Innovative Company of the Year
Researchers suggest in a new study that administering blood tests to lung cancer patients at the time of diagnosis may be able to hasten treatment decisions
GenomeWeb story: Biodesix receives two positive coverage decisions for VeriStrat